Distribution of domperidone into the rat brain is increased by brain ischaemia or treatment with the P-glycoprotein inhibitor verapamil

被引:20
|
作者
Dan, Y [1 ]
Murakami, H [1 ]
Koyabu, N [1 ]
Ohtani, H [1 ]
Sawada, Y [1 ]
机构
[1] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut Medicopharaceut Sci, Higashi Ku, Fukuoka 8128582, Japan
关键词
D O I
10.1211/0022357021778880
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Domperidone (DOM), a peripheral dopamine D2 receptor antagonist, is a substrate of P-glycoprotein (P-gp). Therefore, the transport of DOM into the brain may be restricted by P-gp function at the blood-brain barrier, and when the function of P-gp is impaired by ATP depletion under conditions of brain ischaemia (e.g. cerebral thrombosis), side-effects may be induced as a result of increased distribution of DOM into the brain. In this study, we investigated the effects of brain ischaemia and verapamil, a P-gp inhibitor, on the permeability coefficient-surface area product (PS values) of DOM across the blood-brain barrier by using an in-situ rat brain perfusion technique. The PS values of DOM were increased 3.4- and 3.6-fold after brain ischaemia for 10 and 20 min, respectively. Furthermore, co-administration of verapamil significantly increased the PS values of DOM by 42.6- and 43.3-fold in the normal and ischaemia groups, respectively. Brain vascular volume was not affected by ischaemia or verapamil. These results show that the transport of DOM into the brain is restricted by P-gp and that the brain distribution of DOM can be increased by cerebral ischaemia or co-administration of a P-gp inhibitor.
引用
收藏
页码:729 / 733
页数:5
相关论文
共 50 条
  • [1] Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat
    Rodriguez, M
    Ortega, I
    Soengas, I
    Suarez, E
    Lukas, JC
    Calvo, R
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2004, 56 (03) : 367 - 374
  • [2] Involvement of P-glycoprotein in the brain distribution of blonanserin
    Inoue, Tomoko
    Tagawa, Masaaki
    Osada, Kenichi
    Ogawa, Yuriko
    Haga, Toshihisa
    Sogame, Yoshihisa
    Katsumata, Takashi
    Yamaguchi, Noboru
    Yabuki, Masashi
    DRUG METABOLISM REVIEWS, 2011, 43 : 205 - 205
  • [3] Increased brain P-glycoprotein in morphine tolerant rats
    Aquilante, CL
    Letrent, SP
    Pollack, GM
    Brouwer, KLR
    LIFE SCIENCES, 1999, 66 (04) : PL47 - PL51
  • [4] Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein
    Kemper, EM
    van Zandbergen, AE
    Cleypool, C
    Mos, HA
    Boogerd, W
    Beijnen, JH
    van Tellingen, O
    CLINICAL CANCER RESEARCH, 2003, 9 (07) : 2849 - 2855
  • [5] Increased drug delivery to the brain by P-glycoprotein inhibition
    Sadeque, AJM
    Wandel, C
    He, HB
    Shah, S
    Wood, AJJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (03) : 231 - 237
  • [6] Response of brain specific microenvironment to P-glycoprotein inhibitor: An important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors
    Joo, Kyeung Min
    Song, Sang Yong
    Park, Kwan
    Kim, Mi Hyun
    Jin, Juyoun
    Kang, Bong Gu
    Jang, Mi Jung
    Lee, Gwan Sun
    Kim, Maeng Sup
    Nam, Do-Hyun
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 33 (04) : 705 - 712
  • [7] The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice
    Gallo, JM
    Li, SL
    Guo, P
    Reed, K
    Ma, JG
    CANCER RESEARCH, 2003, 63 (16) : 5114 - 5117
  • [8] Functional expression of P-glycoprotein in rat brain microglia
    Lee, G
    Schlichter, L
    Bendayan, M
    Bendayan, R
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 299 (01): : 204 - 212
  • [9] The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution
    Choong, Eva
    Dobrinas, Maria
    Carrupt, Pierre-Alain
    Eap, Chin B.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2010, 6 (08) : 953 - 965
  • [10] Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil
    Sakugawa, Takashi
    Miura, Masatomo
    Hokama, Nobuo
    Suzuki, Toshio
    Tateishi, Tomonori
    Uno, Tsukasa
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (05) : 535 - 540